Thein Hlaing Oo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4885941/publications.pdf

Version: 2024-02-01

623188 552369 128 976 14 26 g-index citations h-index papers 130 130 130 1420 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Copper deficiency anemia: review article. Annals of Hematology, 2018, 97, 1527-1534.	0.8	176
2	A Co-ligand Complex Anchors Plasmodium falciparum Merozoites to the Erythrocyte Invasion Receptor Band 3. Journal of Biological Chemistry, 2004, 279, 5765-5771.	1.6	91
3	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology, 2019, 94, 563-574.	2.0	51
4	Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nature Clinical Practice Oncology, 2005, 2, 196-201.	4.3	39
5	Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy. Blood Coagulation and Fibrinolysis, 2016, 27, 270-274.	0.5	32
6	Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Research and Treatment, 2020, 183, 479-487.	1.1	30
7	Marantic Endocarditis and Disseminated Intravascular Coagulation With Systemic Emboli in Presentation of Pancreatic Cancer. Journal of Clinical Oncology, 2008, 26, 1383-1385.	0.8	27
8	Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases. Journal of Immunotherapy, 2018, 41, 32-34.	1.2	26
9	Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and metaâ€analysis of randomized controlled trials (RCTs). Asia-Pacific Journal of Clinical Oncology, 2018, 14, 210-216.	0.7	20
10	Bronchus-Associated Lymphoid Tissue Lymphomas. Southern Medical Journal, 2009, 102, 1229-1233.	0.3	17
11	Amiodarone-Associated Bone Marrow Granulomas: A Report of 2 Cases and Review of the Literature. International Journal of Hematology, 2007, 85, 101-104.	0.7	16
12	Pernicious anemia: Pathophysiology and diagnostic difficulties. Journal of Evidence-Based Medicine, 2021, 14, 161-169.	0.7	16
13	Diamond Lamb wave spin-mechanical resonators with optically coherent nitrogen vacancy centers. Journal of Applied Physics, 2019, 126, .	1.1	15
14	Advances in mechanisms, diagnosis, and treatment of pernicious anemia. Discovery Medicine, 2015, 19, 159-68.	0.5	15
15	Thymoma Complicated by Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1505-1509.	2.3	14
16	Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 115-118.	0.6	14
17	Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2017, 43, 233-240.	1.0	13
18	Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency. Current Drug Safety, 2017, 12, 13-18.	0.3	13

#	Article	IF	Citations
19	Difficult Diagnostic and Therapeutic Cases. Journal of Clinical Oncology, 2004, 22, 953-954.	0.8	12
20	Adrenal Hemorrhage Secondary to Metastasis from Lung Cancer. Clinical Lung Cancer, 2002, 4, 183-185.	1.1	11
21	Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians. Thrombosis, 2013, 2013, 1-10.	1.4	11
22	Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Advances in Hematology, 2015, 2015, 1-19.	0.6	11
23	Autoimmune Myelofibrosis and Systemic Lupus Erythematosus in a Middle-Aged Male Presenting Only with Severe Anemia. Medicine (United States), 2015, 94, e741.	0.4	11
24	Wide Variation in Duration of Anticoagulation after Catheter-Related Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. Blood, 2018, 132, 1248-1248.	0.6	11
25	Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2017, 15, 17-22.	0.4	11
26	Amniotic Fluid Embolism Complicated by Paradoxical Embolism and Disseminated Intravascular Coagulation. American Journal of Critical Care, 2010, 19, 379-382.	0.8	10
27	Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. Blood Advances, 2021, 5, 2807-2812.	2.5	10
28	Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysis. Journal of Immunotherapy, 2022, 45, 13-24.	1.2	10
29	Uncommon Presentations of Malignancies. Journal of Clinical Oncology, 2003, 21, 2993-2995.	0.8	9
30	Identifying Hemostatic Thresholds in Cancer Patients Undergoing Coronary Angiography Based on Platelet Count and Thromboelastography. Frontiers in Cardiovascular Medicine, 2020, 7, 9.	1.1	9
31	Current Controversies in Inferior Vena Cava Filter Placement: <i>AJR</i> Expert Panel Narrative Review. American Journal of Roentgenology, 2021, 216, 563-569.	1.0	9
32	Challenging clinical presentations of pernicious anemia. Discovery Medicine, 2017, 24, 107-115.	0.5	9
33	Uncommon Presentations of Malignancies. Journal of Clinical Oncology, 2003, 21, 2995-2996.	0.8	8
34	Sequencing of t(2;7) Translocations Reveals a Consistent Breakpoint Linking CDK6 to the IGK Locus in Indolent B-Cell Neoplasia. Journal of Molecular Diagnostics, 2013, 15, 101-109.	1.2	8
35	Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. Annals of Hematology, 2015, 94, 1605-1607.	0.8	8
36	Copper deficiencyâ€related bone marrow changes secondary to longâ€term total parenteral nutrition. Clinical Case Reports (discontinued), 2017, 5, 195-196.	0.2	8

#	Article	lF	CITATIONS
37	Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center. Journal of Thrombosis and Thrombolysis, 2018, 45, 377-385.	1.0	8
38	Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. Thrombosis Research, 2021, 202, 155-161.	0.8	8
39	Diagnostic difficulties in pernicious anemia. Discovery Medicine, 2019, 28, 247-253.	0.5	8
40	Therapy-related chronic myelomonocytic leukemia with unique chromosomal abnormalities: Monosomy 7 and t(12;17)(p13;q11.2). American Journal of Hematology, 2007, 82, 248-249.	2.0	7
41	Unfavorable Therapeutic Index of Cisplatin/Gemcitabine/Vinorelbine in Advanced non—small-Cell Lung Cancer. Clinical Lung Cancer, 2002, 4, 47-51.	1.1	6
42	Clopidogrel-associated thrombotic thrombocytopenic purpura presenting with coronary artery thrombosis. American Journal of Hematology, 2006, 81, 890-891.	2.0	6
43	Pernicious Anemia With Spuriously Normal Vitamin B12 Level Might Be Misdiagnosed As Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e141-e143.	0.2	6
44	Bleeding Risk in Thrombocytopenic Cancer Patients with Venous Thromboembolism (VTE) Receiving Anticoagulation. Blood, 2012, 120, 3408-3408.	0.6	6
45	Mortality from Cancer-Associated Venous Thromboembolism. Blood, 2014, 124, 4829-4829.	0.6	6
46	Primary Thyroid Lymphoma Presenting With Stridor. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 531-533.	0.6	5
47	Performance of 4T score and heparin–platelet factor 4 antibody in the diagnosis of heparin-induced thrombocytopenia (HIT) in cancer. Journal of Thrombosis and Thrombolysis, 2017, 44, 261-266.	1.0	5
48	Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy. Lung, 2020, 198, 575-579.	1.4	5
49	Possible Association between Hairy Cell Leukemia and Behçet's Disease. Southern Medical Journal, 2003, 96, 323-324.	0.3	5
50	Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies. Supportive Care in Cancer, 2022, 30, 8599-8609.	1.0	5
51	Low–Molecular Weight Heparin Prophylaxis Should Not Be Recommended Even in Highly Selected Patients With Solid Cancer Receiving Outpatient Chemotherapy. Journal of Clinical Oncology, 2013, 31, 4380-4381.	0.8	4
52	Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Design, Development and Therapy, 2014, 8, 2181.	2.0	4
53	Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH: a rebuttal. Journal of Thrombosis and Haemostasis, 2014, 12, 115-116.	1.9	4
54	Low- Molecular Weight Heparins (LMWH) Versus Vitamin K Antagonists (VKAs) in the Treatment and Secondary Prevention of Cancer-Associated Venous Thromboembolism (VTE): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs). Blood, 2016, 128, 1180-1180.	0.6	4

#	Article	IF	Citations
55	Unusual Presentations of Lymphoma. Journal of Clinical Oncology, 2002, 20, 1942-1943.	0.8	3
56	Gastric Relapse of Solitary Bone Plasmacytoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 325-326.	0.6	3
57	Trisomy 8 in a newly diagnosed chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 2005, 156, 94-95.	1.0	3
58	Deep Vein Thrombosis Associated with the New Oral Contraceptive Yasmin®. Southern Medical Journal, 2009, 102, 985-986.	0.3	3
59	Presence of paroxysmal nocturnal hemoglobinuria clones does not exclude inherited bone marrow failure syndromes. European Journal of Haematology, 2014, 93, 171-171.	1.1	3
60	Outpatient thromboprophylaxis with low-molecular-weight heparin in solid tumors: Where do we stand today?. Journal of Thrombosis and Thrombolysis, 2016, 41, 539-540.	1.0	3
61	Successful treatment of aplastic anemia–paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clinical Case Reports (discontinued), 2016, 4, 765-767.	0.2	3
62	Comment on "Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial― Journal of Clinical Oncology, 2016, 34, 515-515.	0.8	3
63	Frequency of venous thromboembolism events during acute inpatient rehabilitation in a comprehensive cancer centre. Journal of Rehabilitation Medicine, 2017, 49, 758-764.	0.8	3
64	Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials. Drugs, 2019, 79, 621-631.	4.9	3
65	Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism. EJHaem, 2020, 1, 448-456.	0.4	3
66	Optimal Timing for Removal of an Upper Extremity Central Catheter When Associated with a Deep Vein Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. Blood, 2019, 134, 325-325.	0.6	3
67	Difficult Diagnostic and Therapeutic Cases. Journal of Clinical Oncology, 2004, 22, 957-958.	0.8	2
68	Translocation (2;7)(p11.2;q22) in a newly diagnosed low-grade B-cell non-Hodgkin lymphoma. Cancer Genetics and Cytogenetics, 2008, 181, 65-66.	1.0	2
69	Vitamin B ₁₂ deficiency – A 21st century perspective. Clinical Medicine, 2015, 15, 402.1-402.	0.8	2
70	Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH: comment. Journal of Thrombosis and Haemostasis, 2015, 13, 323-324.	1.9	2
71	A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation: comment. Journal of Thrombosis and Haemostasis, 2016, 14, 2080-2081.	1.9	2
72	Transdisciplinary Approach to Managing Hepatitis C Virus Infection in Patients at a Tertiary Care Cancer Center. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1185-1188.	2.3	2

#	Article	IF	Citations
73	Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients. Annals of Oncology, 2018, 29, viii606.	0.6	2
74	2019 international clinical practice guidelines for the treatment of venous thromboembolism. Lancet Oncology, The, 2019, 20, e655.	5.1	2
75	Rituximab is Effective in the Treatment of Refractory Immune Thrombocytopenic Purpura Associated with Chronic Lymphocytic Leukemia. Southern Medical Journal, 2005, 98, 1227-1228.	0.3	2
76	Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World Journal of Hepatology, 2013, 5, 332.	0.8	2
77	Uncommon Hematologic Malignancies. Journal of Clinical Oncology, 2003, 21, 4249-4251.	0.8	1
78	Morphologic heterogeneity of acute promyelocytic leukemia: Therapy-related acute promyelocytic leukemia presenting with FAB-M2 morphology. American Journal of Hematology, 2006, 81, 475-476.	2.0	1
79	Leukocytosis may be seen in patients with undiagnosed myelopoliferative disorders, factitious leukocytosis and venous thromboembolism. Thrombosis Research, 2011, 127, 487.	0.8	1
80	Letters to the editor. Journal of the Royal College of Physicians of Edinburgh, The, 2011, 41, 187-190.	0.2	1
81	Low molecular weight heparin or semuloparin should not be recommended for thromboprophylaxis in ambulatory solid cancer patients undergoing chemotherapy. Thrombosis Research, 2012, 130, 821-822.	0.8	1
82	Comments on "Essential Thrombocytosis and Antiphospholipid Antibody Syndrome Causing Chronic Budd-Chiari Syndrome― Indian Journal of Pediatrics, 2012, 79, 1533-1534.	0.3	1
83	The Timing of Thrombophilia Testing is Important: Comment on "Left Main Coronary Artery Thrombus Resulting from Combined Protein C and S Deficiency". Internal Medicine, 2013, 52, 695-695.	0.3	1
84	JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis. Indian Journal of Hematology and Blood Transfusion, 2014, 30, 4-8.	0.3	1
85	Differential Diagnoses of Macrocytic Anemia, Reticulocytosis and Low Serum Haptoglobin in Patients with Myelodysplastic Syndromes/Acute Leukemia: Comment on "Two Cases of Acute Erythroid Leukemia Presenting with Marked Macrocytic Anemia, Reticulocytosis and Hemolysis". Internal Medicine, 2014, 53, 77-77.	0.3	1
86	Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: comment. Journal of Thrombosis and Haemostasis, 2015, 13, 1351-1352.	1.9	1
87	Gaucher disease type 1 first recognized in an elderly patient with thrombocytopenia and lung adenocarcinoma. Clinical Case Reports (discontinued), 2019, 7, 1804-1805.	0.2	1
88	The Clinical Applicability of Primary Thromboprophylaxis in Ambulatory Patients With Pancreatic Cancer. Pancreas, 2021, 50, 494-499.	0.5	1
89	Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. Blood, 2018, 132, 1037-1037.	0.6	1
90	Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy. Blood, 2019, 134, 3469-3469.	0.6	1

#	Article	IF	Citations
91	Pattern of Consultation Referrals for Cytopenia Evaluations to a Hematologist at An Academic Medical Center: The Expanding Role of a Consultant Hematologist. Blood, 2008, 112, 4673-4673.	0.6	1
92	Incidence and Management of Hematological Toxicities Associated with Treatment of Hepatitis C Virus Infection in Cancer Patients. Blood, 2014, 124, 4126-4126.	0.6	1
93	Letters to the editor. Journal of the Royal College of Physicians of Edinburgh, The, 2010, 40, 92-94.	0.2	1
94	Trisomies 3 and 18 in a newly diagnosed chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 2007, 176, 175.	1.0	0
95	Rituximab Can Induce a Durable Response in Refractory Immune Thrombocytopenic Purpura Associated with Chronic Lymphocytic Leukemia: Case Report and Review of the Literature. Clinical Leukemia, 2008, 2, 140-142.	0.2	0
96	Many residents under-report their work hours. BMJ: British Medical Journal, 2011, 342, d2424-d2424.	2.4	0
97	Comments on "Desvenlafaxine as a possible cause of acquired hemophilia― General Hospital Psychiatry, 2011, 33, e11.	1.2	0
98	Hypofibrinogenemia, dysfibrinogenemia or hypodysfibrinogenemia?. Blood Coagulation and Fibrinolysis, 2013, 24, 353-354.	0.5	0
99	Letter to the Editor. Journal of the Royal College of Physicians of Edinburgh, The, 2014, 44, 186-189.	0.2	0
100	Performance of 4T score and HIT Antibody in the Diagnosis of Heparin-Induced Thrombocytopenia in Cancer Patients. American Journal of Clinical Pathology, 2016, 146, .	0.4	0
101	Renal cell carcinoma metastasizing to the myeloproliferative bone marrow. Blood Research, 2018, 53, 9.	0.5	0
102	Reply to M. Alexander et al Asia-Pacific Journal of Clinical Oncology, 2019, 15, 185-185.	0.7	0
103	Secondary erythrocytosis due to hemoglobin San Diego. Baylor University Medical Center Proceedings, 2021, 34, 159-160.	0.2	0
104	Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy. Baylor University Medical Center Proceedings, 2022, 35, 1-5.	0.2	0
105	Rituximab Is Effective in Refractory Adult Immune Thrombocytopenic Purpura Associated with Chronic Lymphocytic Leukemia Blood, 2004, 104, 3952-3952.	0.6	0
106	Hematocrit-Driven Referrals for Measurement of RBC Mass. Is the Natural History of Polycythemia Vera Changing? Blood, 2005, 106, 4960-4960.	0.6	0
107	Amiodarone- Induced Bone Marrow Granulomas Blood, 2005, 106, 4317-4317.	0.6	0
108	The Prevalence of Second Malignancies and Autoimmune Diseases in Patients with Lymphoproliferative Disorders Blood, 2006, 108, 4608-4608.	0.6	0

#	Article	IF	Citations
109	Letters to the editor. Journal of the Royal College of Physicians of Edinburgh, The, 2011, 41, 91-94.	0.2	0
110	Use of Growth Factors in Treatment of Hepatitis C Viral Infection in Cancer Patients. Blood, 2012, 120, 4725-4725.	0.6	0
111	Correspondence. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 451-452.	2.3	O
112	Benefit and Risk of Primary Thromboprophylaxis in Ambulatory Patients with Advanced Pancreatic Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Blood, 2014, 124, 4266-4266.	0.6	0
113	Efficacy of Therapeutic Dose Versus Prophylactic Dose of Anticoagulants in the Primary Prevention of Thrombotic Events in Ambulatory Patients with Solid Malignancies Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Blood, 2014, 124, 4275-4275.	0.6	0
114	Natural history of heparin-induced thrombocytopenia (HIT) in the cancer population Journal of Clinical Oncology, 2016, 34, e18134-e18134.	0.8	0
115	Outcomes of Venous Thromboembolism (VTE) Treatment in Thrombocytopenic Leukemic Patients. Blood, 2016, 128, 4964-4964.	0.6	0
116	Risk of Bleeding from Primary Thromboprophylaxis (PTP) in Patients with Solid Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT). Blood, 2016, 128, 3820-3820.	0.6	0
117	A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT) in Ambulatory Thromboprophylaxis (ATP) in Patients with Lung Cancer Receiving Chemotherapy. Blood, 2016, 128, 3825-3825.	0.6	0
118	Cancer Associated Thrombosis: Focus on Prevention and Treatment of Venous Thromboembolism. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2017, 14, 101-112.	0.4	0
119	Hematologic and Thromboembolic Complications of Cancer and Their Treatment. , 2018, , .		0
120	Diamond Phononic Crystal Spin-Mechanical Resonators with Spectrally-Stable Nitrogen Vacancy Centers., 2019,,.		0
121	Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Locally Advanced or Metastatic Lung Cancer (LC) Receiving Chemotherapy. Blood, 2019, 134, 3466-3466.	0.6	0
122	Diagnostic Performance of Heparin-Platelet Factor 4 Antibodies in the Identification of Heparin-Induced Thrombocytopenia in Cancer Population. Blood, 2019, 134, 4896-4896.	0.6	0
123	A Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Gastrointestinal Cancers Receiving Chemotherapy. Blood, 2019, 134, 3679-3679.	0.6	0
124	Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy. Blood, 2019, 134, 2435-2435.	0.6	0
125	Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with ovarian cancer receiving chemotherapy. Baylor University Medical Center Proceedings, 2022, 35, 1-5.	0.2	0
126	Cancer Associated Thrombosis: Focus on Prevention and Treatment of Venous Thromboembolism. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2016, , .	0.4	0

THEIN HLAING OO

#	Article	IF	CITATIONS
127	The unusual nutritional and toxin-related underproduction anemias: approaching the riddle beyond iron, cobalamin, and folate. Discovery Medicine, 2018, 25, 67-74.	0.5	0
128	Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?. Supportive Care in Cancer, 2022, , .	1.0	0